Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ADH1A | P07327 | 4/20 | 0.39 |
| ▸ | ADH1C | P00326 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 5/20 | 0.31 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 4/20 | 0.31 |
| ▸ | CA2 | P00918 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL1356525 | 1.00 | FDPS (0.44) | FDPSBLMTDP1ADH1AADH1C | |
| Phosphoric Acid SCHEMBL29166215 | 0.87 | FDPS (0.50) | FDPSADH1AADH1CFAAHPHGDH | |
| Phosphoric Acid SCHEMBL30818556 | 0.87 | FDPS (0.50) | FDPSADH1AADH1CFAAHPHGDH | |
| Phosphoric Acid SCHEMBL29166159 | 0.87 | FDPS (0.50) | FDPSADH1AADH1CFAAHPHGDH | |
| Phosphoric Acid SCHEMBL29166160 | 0.87 | FDPS (0.50) | FDPSADH1AADH1CFAAHPHGDH | |
| Phosphoric Acid SCHEMBL29166211 | 0.87 | FDPS (0.50) | FDPSADH1AADH1CFAAHPHGDH | |
| Phosphoric Acid SCHEMBL727986 | 0.87 | FDPS (0.50) | FDPSADH1AADH1CFAAHPHGDH | |
| Methyl Alcohol SCHEMBL2135197 | 0.77 | PHGDH (0.46) | FDPSADH1AADH1CFAAHPHGDH | |
| SCHEMBL13356252 | 0.76 | ADH1A (0.50) | TDP1ADH1AADH1CFAAHPHGDH | |
| SCHEMBL283931 | 0.76 | ADH1A (0.50) | TDP1ADH1AADH1CFAAHPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503768-B1 | Inositol pyrophosphates, and use thereof | NORMOXYS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9078908-B2 | Inositol pyrophosphates, and methods of use thereof | NORMOXYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140170127-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | GMP/OXYCELL, INC. | 2014-06-19 | — | — | US | disclosed |
| US-20130059820-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | NORMOXYS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-8178514-B2 | Inositol pyrophosphates, and methods of use thereof | NORMOXYS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110281825-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | Normoxys (US) | 2011-11-17 | — | — | US | disclosed |
| US-7919481-B2 | Inositol pyrophosphates, and methods of use thereof | NORMOXYS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100256094-A1 | Inositol pyrophosphates, and methods of use thereof | NORMOXYS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7648970-B2 | Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders | NORMOXYS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7618954-B2 | Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders | NORMOXYS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070207986-A1 | Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders | NORMOXYS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7084115-B2 | Supplying oxygen to cells; antiischemic agents; cardiovascular disorders | OXYPLUS, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060116358-A1 | Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders | NORMOXYS, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1503768-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | GMP Oxycell, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040014642-A1 | Supplying oxygen to cells; antiischemic agents; cardiovascular disorders | NORMOXYS, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003092700-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | GMP OXYCELL, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014642-A1 | Supplying oxygen to cells; antiischemic agents; cardiovascular disorders | PPIP5K2, ITPA, DHPS | FDPS 230/4885BLM 4682/4885TDP1 4031/4885 |
| US-20060116358-A1 | Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders | PPIP5K2, ITPA, INPP5B | FDPS 285/4885BLM 3943/4885TDP1 3320/4885 |
| US-20140170127-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | PPIP5K2, ITPA, INPP5B | FDPS 88/4885BLM 4385/4885TDP1 3201/4885 |
| US-20110281825-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | PPIP5K2, ITPA, INPP5B | FDPS 128/4885BLM 4066/4885TDP1 2649/4885 |
| US-20100256094-A1 | Inositol pyrophosphates, and methods of use thereof | PPIP5K2, ITPA, INPP5B | FDPS 88/4885BLM 4385/4885TDP1 3201/4885 |
| US-20130059820-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | PPIP5K2, ITPA, INPP5B | FDPS 128/4885BLM 4066/4885TDP1 2649/4885 |
| US-20070207986-A1 | Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders | PPIP5K2, ITPA, INPP5B | FDPS 472/4885BLM 3795/4885TDP1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.